Neurobehavioral problems associated with phenylketonuria

Psychiatry (Edgemont)

Volumn 7, Issue 12, 2010, Pages 29-32

  Targum, Steven D ^a   Lang, William ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE 4 MONOOXYGENASE; SAPROPTERIN;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BLOOD BRAIN BARRIER; COGNITION; DEPRESSION; DRUG EFFICACY; FEEDING BEHAVIOR; HUMAN; MENTAL DEFICIENCY; METABOLIC REGULATION; MOOD DISORDER; MYELIN SHEATH; PANIC; PATIENT CARE; PHENYLKETONURIA; PHOBIA; PROTEIN METABOLISM; SOCIAL COMPETENCE;

EID: 79951559138     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Jervis GA. Phenylpyruvic oligophrenia. Arch Neurol Psychiatry. 1937;38:944.
2. Brumm VI, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab. 2010;99:559-563.
3. Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics. 2003;112 (6):1523-1529.
4. Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: A collaborative study. J Inherit Metab Dis. 2002;25:333-346.
5. Pietz J, Fatkenheuer B, Burgard P, et al. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics. 1997;99:345-350.
6. Simon E, Schwarz M, Roos J, et al. Evaluation of quality of life and description of the sociodemographic state of adolescent and young adult patients with phenylketonuria. Health Qual Life Outcomes. 2008;6;25.
7. Weglage J, Funders B, Wilken B, et al. Psychological and social findings in adolescents with phenylketonuria. Eur J Pediatr. 1992:151:52-525.
8. Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr. 2000; 159:S109-S113.